EIGHTEENTH CONGRESS OF THE REPUBLIC 
OF THE PHILIPPINES
First Regular Session
SENATE
s.B. NO. 834
-
v^T-«; iWJi -f a;' t :: S' ■ . tr rj»
19 JOL30 P513
Introduced by Senator Maria Lourdes Nancy S. Binay
RECci'.- u
AN ACT
ESTABLISHING A STANDARD OF CARE AND TREATMENT CENTERS FOR 
PERSONS W ITH BLEEDING DISORDERS, AND APPROPRIATING FUNDS 
THEREFOR
EXPLANATORY NOTE
Article II, Section 15 of the 1987 Philippine Constitution provides:
"The State shall protect and promote the right to health of the 
people and instill health consciousness among them."
Article XIII, Section 11 of the 1987 Philippine Constitution provides:
"The State shall adopt and integrated and comprehensive approach 
to health development which shall endeavor to make essential 
goods, health and other social services available to all the people at 
affordable cost. There shall be priority for the needs of the 
underprivileged sick, elderly, disabled, women, and children. The 
State shall endeavor to provide free medical care to paupers."
A bleeding disorder is a condition that affects the way that blood normally clots. 
Bleeding disorders can cause abnormal bleeding both outside and inside the 
body. According to the World Federation of Hemophilia, the most common types 
of bleeding disorders are hemophilia and von Willebrand disease (VWD).


Hemophilia is a bleeding disorder that affects approximately 1 in 10,000 people. 
People with hemophilia do not have enough clotting factor VIII or IX in their 
blood which resuits in longer periods of bleeding.
The von Willebrand disease (VWD) is a bleeding disorder caused by a deficiency 
of the von Willebrand factor (VWF), which is a type of protein that helps blood 
platelets clump together. Low functioning levels of VWF disables platelets to clot 
properly and leads to prolonged bleeding.
In the Philippines, approximately one million Filipinos have VWD or another type 
of bleeding disorder while around 10,000 Filipinos are hemophiliacs. As a result 
of lack of information and awareness, there are patients of bleeding disorders 
that died without receiving diagnosis or treatment.
This biil seeks to establish hemophiiia treatment facilities nationwide in 
designated hospitals with Cancer and Hematology Departments to provide free of 
charge blood clotting products, room exclusivity for hemophiiia patients, and 
clinicai coagulation laboratories.
In view of the foregoing the immediate passage of this measure is earnestiy 
sought.
.(L
MARIA LOURDES NAI^Y S. BINAY 
Senator


EIGHTEENTH CONGRESS OF THE REPUBLIC 
) 
OF THE PHILIPPINES 
)
First Regular Session 
)
sena?34
S.B. NO
*19 JUL 30 P5:13
- f -
Introduced by Senator Maria Lourdes Nancy S. Binay
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16 
17
to:
AN ACT
ESTABLISHING A STANDARD OF CARE AND TREATMENT CENTERS FOR 
PERSONS W ITH BLEEDING DISORDERS, AND APPROPRIATING FUNDS 
THEREFOR
Be it enacted by the Senate and House o f Representatives o f the Phiiippines in 
Congress assembied:
Section 1. Short Tide. -  This Act shall be known as the "Bleeding Disorder 
Standards of Care Act of 2019."
Sec. 2. Deciaration o f Poiicy. -  It is hereby declared the policy of the State
(a) Ensure the adequate treatment of hemophilia at the lowest 
possible cost and endeavor to make them available for free 
to indigent patients;
(b) Ensure the establishment of treatment centers in public 
hospitals; and
(c) Establish a standard of care so that patients with severe 
bleeding disorders can receive necessary and appropriate 
medical care.
Sec. 3. Definition o f Terms. -  As used in this Act, the terms:
(a) "Bleeding Disorder" shall refer to a medical condition 
characterized by a severe deficiency or absence of one or


2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
26
27
28
29
30
1
more essential blood clotting proteins in the human blood, 
often called factors, including all forms of hemophilia, von 
Willebrand disease and other bleeding disorders which 
result in uncontrolled bleeding or abnormal blood clotting;
(b) "Blood Clotting product" shall mean an intravenously 
administered medicine manufactured from human plasma, 
recombinant biotechnology techniques and other processes, 
approved for distribution by the BFAD and which is used for 
the treatment and prevention of symptoms associated with 
bleeding disorders. The term includes, but is not limited to:
(1) Factor Vila, Factor VIII and Factor IX products;
(2) Von Willebrand Factor products;
(3) Prothrombin complex concentrates;
(4) Activated prothrombin complex concentrates; 
and
(5) Other products approved by the BFAD for the 
treatment of bleeding disorders and associated 
inhibitors;
(c) "Indigent Patient" shall mean any patient deemed unable to 
pay for services or medical treatment, laboratory testing of 
blood and/or coagulation studies, or blood coagulating 
product and/or ancillary infusion equipment;
(d) "DOFI" shall refer to the Department of Health;
(e) "BFAD" shall refer to the Bureau of Food and Drugs;
(f) "Hemophilia" shall refer to a human bleeding disorder 
caused by a hereditary deficiency of the Factor VIII, Factor 
XI or Factor XI blood clotting protein in human blood; and
(g) "von Willebrand disease" shall refer to a human bleeding 
disorder caused by a hereditary deficiency or abnormality of 
the von Willebrand Factor in human blood;
2


2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
26
27
28 
29
1
Sec. 4. State Treatment Facilities. -  The State shall establish hemophilia 
treatment facilities in key cities and regions nationwide in designated hospitals 
with Cancer and Hematology Departments.
Each Hemophilia Treatment Facilities shall provide to all hemophilia 
patients:
(a) Care by qualified hematologists and medical doctors and 
shall also provide free of charge the necessary blood 
clotting 
products 
and 
ancillary 
infusion 
equipment 
necessary for the infusion of such blood clotting products;
(b) A room exclusively for hemophilia patients; and
(c) A 
clinical 
coagulation 
laboratory 
for 
the 
screening, 
diagnosis, provisional diagnosis and treatment of bleeding 
disorders or suspected bleeding disorders and such services 
shall be provided free of charge to all indigent patients.
Sec. 5. Funding. -  The amount necessary for the initial implementation of 
this Act shall be sourced from the current budget of the Department of Health. 
Thereafter, the funds necessary for the continuous implementation of this Act in 
the ensuing years shall be included in the General Appropriations Act.
The treatment facilities are allowed to use five percent (5%) of the 
amount given to it for the maintenance of the rooms that will be used exclusively 
for hemophilia patients. However, ninety percent (90%) of the amount shall be 
used exclusively for necessary blood clotting products and ancillary infusion 
equipment necessary for the infusion of such blood clotting products to 
hemophilia patients. The remaining five percent (5%) shall be used for blood 
screening of hemophilia patients.
Each treatment facility shall submit an annual report to the DOH on how 
the amount given to it is used.


2
3
4
5
6
7
8 
9
10
11
1
Sec. 6. Implementing Rules and Regulations. -  Within sixty (60) days from 
the approval of this Act, the Department of health shall, in consultation with 
hemophilia groups, promulgate the Implementing Rules and Regulations (IRR) to 
carry out the provisions of this Act.
Sec. 7. Separability Clause. -  If for any reason, any provision of this Act is 
declared unconstitutional or invalid, the other parts or provisions hereof which 
are not affected thereby shall continue to be in full force and effect.
Sec. 8. Effectivity Clause. -  This Act shall take effect fifteen (15) days 
following its publication in at least two (2) newspapers of national circulation.
Approved,